Moriguchi M, Suzuki T, Tateishi M, Hara M, Kashiwazaki S
Institute of Rheumatology, Tokyo Women's Medical College.
Intern Med. 1996 Aug;35(8):663-7. doi: 10.2169/internalmedicine.35.663.
The efficacy of polyvalent intravenous immunoglobulin therapy (IVIG) was evaluated in three patients with refractory myositis. Patients refractory to conventional therapy, such as corticosteroid administration, corticosteroid or cyclophosphamide pulse therapy [2 with dermatomyositis (DM), 1 with polymyositis (PM)] were treated with IVIG (0.4 g/kg daily) for 5 days. Clinical improvement was apparent within 1-2 months after IVIG and persisted for 19-23 months (DM patients) and 12 months (PM patient). No adverse effects were observed. Thus, IVIG may be considered an effective therapy for refractory myositis.
对三名难治性肌炎患者评估了多价静脉注射免疫球蛋白疗法（IVIG）的疗效。对常规治疗（如给予皮质类固醇、皮质类固醇或环磷酰胺冲击疗法）无效的患者（2例皮肌炎患者、1例多发性肌炎患者）接受了IVIG治疗（每日0.4 g/kg），持续5天。IVIG治疗后1 - 2个月内临床改善明显，且在皮肌炎患者中持续了19 - 23个月，在多发性肌炎患者中持续了12个月。未观察到不良反应。因此，IVIG可被视为难治性肌炎的一种有效治疗方法。
